|
WO2021073623A1
|
|
Method for preparing isoquinolinone compounds
|
|
CN111393444A
|
|
Preparation method of abacavir hydroxy acetate
|
|
CN111018725A
|
|
Preparation method of (1R,3S) -3-aminocyclopentanol chiral acid salt
|
|
CN110922395A
|
|
Novel crystal form of canagliflozin and preparation method thereof
|
|
CN109867664A
|
|
The preparation method of nucleoside analog Lamivudine
|
|
CN109206396A
|
|
2-C- methyl -4,5-O- (1- methyl ethylene)-D-arabinose acetoacetic ester preparation method
|
|
CN109206419A
|
|
Sha Ku is than bent intermediate and its preparation method and application
|
|
CN108727171A
|
|
4,4 '-two（2- acetyl bromides）The preparation method of biphenyl
|
|
CN105294760A
|
|
Preparation method for low-melting-point crystal form of tenofovir disoproxil fumarate
|
|
CN105294679A
|
|
Preparation method for praziquantel
|
|
CN105315280A
|
|
Abacavir crystal and preparation method thereof
|
|
CN105152900A
|
|
Preparation method for atovaquone III type crystal
|
|
CN105315203A
|
|
V-type elvitegravir crystal and preparation method thereof
|
|
CN105294556A
|
|
Method for preparing montelukast acid
|
|
CN105272922A
|
|
Method for 5-fluorocytosine
|
|
CN105130875A
|
|
Saxagliptin and saxagliptin salt preparation method
|
|
CN104860897A
|
|
Intermediate for preparing N-cyclopropyl-(2S, 3S)-3-amino-2-hydroxy caproamide, preparation method and applications thereof
|
|
CN104725395A
|
|
Technology for preparing beta-artemether
|
|
CN104725452A
|
|
Method for preparing beta-thymidine
|
|
CN104672239A
|
|
Process for preparing abacavir intermediate in formula V by adopting one-pot method
|
